Neuroprotective implant for treatment of glaucoma in phase II trial

Article
Conferences|ASCRS

Here's the latest innovations at Neurotech Pharmaceuticals, Inc. 

Rich Small, CPA, CEO of Neurotech Pharmaceuticals, Inc., shares what's in the pipeline for retina, glaucoma therapies. 

Recent Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Lorraine Provencher, MD, presenting slides
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Deb Ristvedt, DO's CIME 2024 Talk Highlights Innovations in Treating Glaucoma via the Trabecular Meshwork
Related Content
ChatGPT may have a future use in glaucoma

ChatGPT may have a future use in glaucoma

Article
Assessing the Evidence for Extending Treatment Intervals in nAMD & DME Management: Expert Insights into Innovative Approaches

Assessing the Evidence for Extending Treatment Intervals in nAMD & DME Management: Expert Insights into Innovative Approaches

Podcast
Nicox announces recruitment of last patient in US in Denali Phase 3 trial of NCX 470

Nicox announces recruitment of last patient in US in Denali Phase 3 trial of NCX 470

Article
Ehsan Sadri, MD, leads an ophthalmology innovation discussion with Jeffry Weinhuff of Visionary Ventures

(EyePod) From idea to impact: Navigating ophthalmic innovation

Podcast
Stress resilience–enhancing drugs: New class of small molecules holds promise

Stress resilience–enhancing drugs: New class of small molecules holds promise

Article
Richard Rosen, MD, honored with distinguished award from ASRS

Richard Rosen, MD, honored with distinguished award from ASRS

Article
© 2024 MJH Life Sciences

All rights reserved.